Natarajan Sethuraman, PhD, Elevated to President of R&D at Entrada Therapeutics

BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. TRDA has announced the promotion of Natarajan Sethuraman, PhD, to President of Research and Development. This step reflects the company's commitment to leadership in innovative therapeutic development. Entrada Therapeutics is a clinical-stage biopharmaceutical company at the forefront of creating a new class of medicines through its proprietary Endosomal Escape Vehicle (EEV™) technology.

Entrada's Innovative EEV™ Therapeutics

With a firm focus on the development of EEV™ therapeutics, Entrada Therapeutics is dedicated to revolutionizing the way treatment is delivered inside patients' cells. Their technology is designed to address the challenges of intracellular delivery, aiming to provide life-altering benefits to patients with serious conditions who currently have limited treatment options.

Progress Under Sethuraman's Leadership

Under Dr. Sethuraman's guidance, Entrada Therapeutics has made significant strides in R&D, propelling the company towards achieving its mission of delivering transformative therapies. The elevation of Dr. Sethuraman to President of R&D underscores the company's strategy to integrate innovative research with comprehensive development efforts.

Biopharmaceutical, Promotion, Innovation